Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae – Authors' reply

[...]we did several multivariate analyses, including models with the individual variables, models with the scores, and models with both, after checking for collinearity. [...]we stated that differences in clinical performance could not be discounted according to the Breslow test. BGG declares no competing interests. 1 B Gutiérrez-Gutiérrez, E Salamanca, M de Cueto, Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study, Lancet Infect Dis, Vol. 17, 2017, 726-734 2 SE Boyd, LSP Moore, TM Rawson, WW Hope, AH Holmes, Combination therapy for carbapenemase-producing Enterobacteriaceae: INCREMENT-al effect on resistance remains unclear, Lancet Infect Dis, Vol. 17, 2017, 899-900 3 M Paul, A Lador, S Grozinsky-Glasberg, L Leibovici, Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis, Cochrane Database Syst Rev, Vol. 1, 2014, CD003344.